Ep. 359 - 2Q markets preview, tariffs and biotech takeouts | BioCentury This Week

The podcast explores the biotech industry's resilience amid global uncertainties, focusing on M&A activity and potential impacts of the Middle East conflict. It highlights the sector's strong performance in the first quarter, driven by M&A deals and positive clinical readouts, but notes concerns about prolonged conflict leading to higher oil prices and interest rates, particularly affecting smaller companies. The discussion also covers the potential impact of Vinay Prasad's departure from the FDA on regulatory predictability and Trump's proposed pharma tariffs, which aim to coerce companies into MFN deals, potentially impacting smaller firms reliant on overseas manufacturing. Recent M&A deals by Eli Lilly and Biogen are examined for their strategic implications and potential growth drivers.

Outlines

Part 1: Market Trends, Events

Part 2: Economic Risks, Sector Resilience

Part 3: Regulation, Policy, Tariffs

Part 4: M&A Case Studies, Strategy

Sign in to continue reading, translating and more.

Continue

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

BioCentury This Week

Part 1: Market Trends, Events

Biotech's Resilience Amidst Global Uncertainty and BioEquity Europe Preview

BioCentury's Presence at BioEquity Europe and the Impact of Middle East Conflict on Biotech

Part 2: Economic Risks, Sector Resilience

Assessing Biotech's Vulnerability: Prolonged Conflict and Interest Rate Impacts

Biotech as a Safe Haven and the Resilient Performance Driven by M&A

Part 3: Regulation, Policy, Tariffs

IPO Market Challenges and FDA Predictability Concerns

Trump's Threatened Pharma Tariffs: Coercion and Potential Impacts

Trade Organizations Sidelined and CPath's Initiative for Rare Conditions

Part 4: M&A Case Studies, Strategy

Lilly's Acquisition of Centessa: Expanding Potential Beyond Narcolepsy

Sleep Disorders and Lilly's Strategic Pipeline Expansion

Biogen's Acquisition of Apellis: Growth Drivers and Debt Considerations

Biogen's Strategic Fit and BioEquity Europe Invitation

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

BioCentury This Week

Part 1: Market Trends, Events

00:22Biotech's Resilience Amidst Global Uncertainty and BioEquity Europe Preview

Biotech's Resilience Amidst Global Uncertainty and BioEquity Europe Preview

02:29BioCentury's Presence at BioEquity Europe and the Impact of Middle East Conflict on Biotech

BioCentury's Presence at BioEquity Europe and the Impact of Middle East Conflict on Biotech

Part 2: Economic Risks, Sector Resilience

06:16Assessing Biotech's Vulnerability: Prolonged Conflict and Interest Rate Impacts

Assessing Biotech's Vulnerability: Prolonged Conflict and Interest Rate Impacts

09:51Biotech as a Safe Haven and the Resilient Performance Driven by M&A

Biotech as a Safe Haven and the Resilient Performance Driven by M&A

Part 3: Regulation, Policy, Tariffs

13:34IPO Market Challenges and FDA Predictability Concerns

IPO Market Challenges and FDA Predictability Concerns

16:46Trump's Threatened Pharma Tariffs: Coercion and Potential Impacts

Trump's Threatened Pharma Tariffs: Coercion and Potential Impacts

23:02Trade Organizations Sidelined and CPath's Initiative for Rare Conditions

Trade Organizations Sidelined and CPath's Initiative for Rare Conditions

Part 4: M&A Case Studies, Strategy

26:33Lilly's Acquisition of Centessa: Expanding Potential Beyond Narcolepsy

Lilly's Acquisition of Centessa: Expanding Potential Beyond Narcolepsy

30:03Sleep Disorders and Lilly's Strategic Pipeline Expansion

Sleep Disorders and Lilly's Strategic Pipeline Expansion

32:21Biogen's Acquisition of Apellis: Growth Drivers and Debt Considerations

Biogen's Acquisition of Apellis: Growth Drivers and Debt Considerations

36:09Biogen's Strategic Fit and BioEquity Europe Invitation

Biogen's Strategic Fit and BioEquity Europe Invitation